Cohance Lifesciences Ltd vs Walpar Nutritions Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 482.95 as of 30 Apr 15:30 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Walpar Nutritions Ltd changed from 32.1 on March 2022 to 17.1 on March 2025 . This represents a CAGR of -14.57% over 4 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Walpar Nutritions Ltd changed from ₹ 12.26 crore on March 2022 to ₹ 39.72 crore on March 2025 . This represents a CAGR of 34.16% over 4 years The revenue of Cohance Lifesciences Ltd for the Dec '25 is ₹ 550.71 crore as compare to the Sep '25 revenue of ₹ 571.17 crore. This represent the decline of -3.58% The revenue of Walpar Nutritions Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Cohance Lifesciences Ltd for the Dec '25 is ₹ 96.65 crore as compare to the Sep '25 ebitda of ₹ 136.55 crore. This represent the decline of -29.22% The ebitda of Walpar Nutritions Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 29.02 crore over 7 quarters. This represents a CAGR of -42.04% The net profit of Walpar Nutritions Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Walpar Nutritions Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Walpar Nutritions Ltd

Walpar Nutritions Limited was originally formed and registered as a Partnership Firm in the name and style of 'M/s Walpar Healthcare', pursuant to a Deed of Partnership dated November 16, 2009.
Subsequently, the Constitution of Partnership Firm were changed on March 9, 2015, August 15, 2017 and June 12, 2020 by admission and retirement of Partners. 'M/s.
Walpar Healthcare' was thereafter converted from a erstwhile Partnership Firm to a Public Limited Company as 'Walpar Nutritions Limited' and received a Certificate of Incorporation dated December 4, 2020 from the Central Registration Center, Ministry of Corporate Affairs.
The Company is primarily engaged in manufacturing, marketing and trading of Pharmaceuticals, Nutraceutical, Herbal and Ayurvedic commodities online and offline. The Company made a public issue of 12,00,000 Equity Shares of having Face Value of Rs.

FAQs for the comparison of Cohance Lifesciences Ltd and Walpar Nutritions Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Walpar Nutritions Ltd?

Market cap of Cohance Lifesciences Ltd is 18,476 Cr while Market cap of Walpar Nutritions Ltd is 34 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Walpar Nutritions Ltd?

The stock performance of Cohance Lifesciences Ltd and Walpar Nutritions Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Walpar Nutritions Ltd?

As of May 4, 2026, the Cohance Lifesciences Ltd stock price is INR ₹482.95. On the other hand, Walpar Nutritions Ltd stock price is INR ₹37.0.

How do dividend payouts of Cohance Lifesciences Ltd and Walpar Nutritions Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Walpar Nutritions Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.